PIK3CA and breast carcinoma: Pan-PI3K inhibitors have fared poorly in clinical trials due to their toxicity, while the isoform-specific PI3K inhibitor, alpelisib, has been approved by the FDA as co-therapy with fulvestrant for patients with ER-positive, PI3Kalpha mutated advanced breast cancer (139).